Rett will be filed before AD and Rett approval will make Anavex a revenue producing company.
Rett is what is keeping me sane when it comes to AVXL. My personal share price projections (only back of envelope stuff) show an AVXL price after two years into commercialization at $80/share. That assumes a slow ramp with a very conservative number of treatments.